MetLife (MET) Stock Forecast & Price Target

$84.09 -0.09 (-0.11%)

As of 01:55 PM Eastern

MetLife - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 13 Analyst Ratings

Sell
0

Hold
1

Buy
12

Based on 13 Wall Street analysts who have issued ratings for MetLife in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 13 analysts, 1 has given a hold rating, and 12 have given a buy rating for MET.

Consensus Price Target

$94.58
12.48% Upside

According to the 13 analysts' twelve-month price targets for MetLife, the average price target is $94.58. The highest price target for MET is $109.00, while the lowest price target for MET is $80.00. The average price target represents a forecasted upside of 12.48% from the current price of $84.09.

Get the Latest News and Ratings for MET and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for MetLife and its competitors.

MET Analyst Ratings Over Time

Type	Current Forecast 3/25/24 to 3/25/25	1 Month Ago 2/24/24 to 2/23/25	3 Months Ago 12/26/23 to 12/25/24	1 Year Ago 3/26/23 to 3/25/24
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	12 Buy rating(s)	11 Buy rating(s)	13 Buy rating(s)	12 Buy rating(s)
Hold	1 Hold rating(s)	1 Hold rating(s)	0 Hold rating(s)	1 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$94.58	$92.58	$88.62	$77.23
Forecasted Upside	12.48% Upside	14.28% Upside	7.74% Upside	5.65% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Buy	Moderate Buy

Remove Ads

MET Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

MET Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

MetLife Stock vs. The Competition

Type	MetLife	Finance Companies	S&P 500
Consensus Rating Score	2.92	2.52	2.54
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	11.91% Upside	44.23% Upside	17.16% Upside
News Sentiment Rating	Positive News See Recent MET News	Positive News	Positive News

Remove Ads

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
3/7/2025	Cowen 1 of 5 stars		Reiterated Rating	Buy ➝ Buy
2/28/2025	Morgan Stanley 3 of 5 stars	Nigel Dally Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Overweight ➝ Overweight	$101.00 ➝ $109.00	+28.10%
2/19/2025	Wells Fargo & Company 3 of 5 stars	Elyse Greenspan Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Overweight ➝ Overweight	$92.00 ➝ $97.00	+17.84%
2/12/2025	Keefe, Bruyette & Woods Subscribe to MarketBeat All Access for the recommendation accuracy rating	Ryan Krueger Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Outperform ➝ Outperform	$100.00 ➝ $98.00	+17.73%
2/7/2025	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	A. Scott Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Overweight ➝ Overweight	$96.00 ➝ $95.00	+13.10%
1/23/2025	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Jack Matten Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Market Perform	$97.00	+13.09%
1/7/2025	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$86.00 ➝ $88.00	+6.59%
11/27/2024	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	A. Kligerman Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$97.00 ➝ $99.00	+11.50%
10/2/2024	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$85.00 ➝ $92.00	+12.46%
9/27/2024	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$89.00 ➝ $95.00	+14.71%
Get the Latest News and Ratings for MET and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for MetLife and its competitors with MarketBeat's FREE daily newsletter.
8/1/2024	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$99.00 ➝ $96.00	+24.92%
7/23/2024	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$83.00 ➝ $89.00	+18.26%
5/22/2024	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$77.00 ➝ $80.00	+9.50%
2/5/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$87.00 ➝ $82.00	+24.05%
1/8/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Neutral ➝ Buy	$70.00 ➝ $80.00	+16.08%
10/4/2023	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Hold	$71.00	+18.33%
8/4/2023	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$70.00 ➝ $74.00	+14.14%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 01:55 PM ET.

Should I Buy MetLife Stock? MET Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Saturday, March 22, 2025. Please send any questions or comments about these MetLife pros and cons to contact@marketbeat.com.

MetLife
Bull Case

Here are some ways that investors could benefit from investing in MetLife, Inc.:

MetLife, Inc. has a strong consensus rating of "Moderate Buy" from analysts, indicating positive sentiment and potential for stock appreciation.
The stock is currently priced at $82.33, which is below its twelve-month high of $89.05, suggesting potential upside for investors looking for growth.
Recent upgrades from major financial institutions, such as JPMorgan Chase & Co. raising their target price to $88.00, reflect confidence in the company's future performance.
MetLife, Inc. has a solid dividend yield of 2.65%, providing investors with a steady income stream, which is attractive in a low-interest-rate environment.
The company reported a return on equity of 20.42%, indicating efficient management and profitability, which can lead to higher shareholder value.

MetLife
Bear Case

Investors should be bearish about investing in MetLife, Inc. for these reasons:

MetLife, Inc. recently missed earnings expectations, reporting $2.08 per share against a consensus estimate of $2.13, which may raise concerns about its short-term performance.
The company's quick ratio and current ratio are both at 0.16, indicating potential liquidity issues, as these ratios measure the ability to cover short-term liabilities with short-term assets.
Despite a strong market cap of $56.09 billion, the stock's price-to-earnings (P/E) ratio of 13.79 may suggest that it is overvalued compared to its earnings, which could deter value-focused investors.
Analysts have varying target prices, with some estimates as low as $98.00, indicating uncertainty in the stock's future trajectory.
The company operates in a competitive financial services market, which could impact its ability to maintain market share and profitability in the long run.

MET Forecast - Frequently Asked Questions

: According to the research reports of 13 Wall Street equities research analysts, the average twelve-month stock price forecast for MetLife is $94.58, with a high forecast of $109.00 and a low forecast of $80.00.
: 13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MetLife in the last twelve months. There is currently 1 hold rating and 12 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" MET shares.
: According to analysts, MetLife's stock has a predicted upside of 12.48% based on their 12-month stock forecasts.
: MetLife has been rated by research analysts at Barclays, BMO Capital Markets, Cowen, JPMorgan Chase & Co., Keefe, Bruyette & Woods, Morgan Stanley, and Wells Fargo & Company in the past 90 days.
: Analysts like MetLife more than other "finance" companies. The consensus rating score for MetLife is 2.92 while the average consensus rating score for "finance" companies is 2.53. Learn more on how MET compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top-Rated Stocks

More Ratings Tools

This page (NYSE:MET) was last updated on 3/25/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

MetLife (MET) Stock Forecast & Price Target